Dr. Sokolow has a broad background in pharmacology and neurobiology of Alzheimer’s disease (AD), with specific training and expertise in molecular biology, clinical pharmacy and pharmacogenomics with emphasis in analyzing secondary data of drug response in the treatment of cognitive symptoms of AD and mild cognitive impairment (MCI). Her research program examines two main area of Alzheimer’s Disease (AD): 1) the molecular pathogenesis of AD in surviving nerve terminals and 2) the influence of genetics on the response to therapy in AD and mild cognitive impairment (MCI). Her current research project focuses on the discovery of genetic polymorphisms associated with response to AD medications, such as donepezil and other acetylcholinesterase inhibitors. Her early studies aimed at understanding the molecular repercussion of intrasynaptic amyloid-beta buildup in the development of AD. This includes studies investigating the role of intrasynaptic amyloid-beta and tau on glutamate and calcium signaling pathways (e.g. sodium-calcium exchange). Areas of Scholarly Expertise and Interest: Alzheimer’s disease, genetics, pharmacogenomics, pharmacology and therapeutics, biomarkers, calcium signaling pathways.
Research: Alzheimer’s disease, genetics, pharmacogenomics, biomarkers, calcium signaling pathways. Clinical: , clinical pharmacy, pharmacovigilance and pharmacosurveillance.